Get the Stockscreener App
8.53
0.00%
0.00
Y Mabs Therapeutics Inc stock is traded at $8.53, with a volume of 573.84K.
It is up +0.00% in the last 24 hours and up +93.42% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$8.53
Open:
$8.53
24h Volume:
573.84K
Relative Volume:
0.81
Market Cap:
$387.59M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-17.41
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
+0.12%
1M Performance:
+93.42%
6M Performance:
+49.13%
1Y Performance:
-35.96%
1-Day Range:
$8.53
$8.54
1-Week Range:
$8.5113
$8.54
52-Week Range:
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
646-885-8505
Address
202 CARNEGIE CENTER, PRINCETON, NY
Compare YMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
8.53 | 387.14M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-24 | Initiated | Oppenheimer | Outperform |
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Halper Sadeh Investigates Veritex, TaskUs, Y-mAbs Merger Activity - AInvest
Ranking Y mAbs Therapeutics Inc. among high performing stocks via toolsEarnings Risk Summary & Short-Term Trading Alerts - Newser
How to interpret RSI for Y mAbs Therapeutics Inc. stockMarket Growth Review & Safe Swing Trade Setups - Newser
Is this a good reentry point in Y mAbs Therapeutics Inc.Quarterly Earnings Summary & Stepwise Trade Execution Plans - Newser
Can volume confirm reversal in Y mAbs Therapeutics Inc.2025 Price Momentum & Verified Swing Trading Watchlists - Newser
Will Y mAbs Therapeutics Inc. outperform the marketTrade Exit Summary & Verified Entry Point Signals - Newser
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY - GlobeNewswire
Will Y mAbs Therapeutics Inc. continue its uptrendJuly 2025 Spike Watch & Daily Oversold Bounce Ideas - Newser
Long term hold vs stop loss in Y mAbs Therapeutics Inc.Fed Meeting & Growth Focused Stock Pick Reports - Newser
Can trapped investors hope for a rebound in Y mAbs Therapeutics Inc.July 2025 WrapUp & Risk Adjusted Swing Trade Ideas - Newser
Custom strategy builders for tracking Y mAbs Therapeutics Inc.Market Sentiment Review & Free Technical Pattern Based Buy Signals - Newser
Y-mAbs Therapeutics (NASDAQ:YMAB) and Viridian Therapeutics (NASDAQ:VRDN) Financial Survey - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNOW, TASK, YMAB on Behalf of Shareholders - The Malaysian Reserve
Measuring Y mAbs Therapeutics Inc.’s beta against major indicesIndex Update & AI Driven Price Forecasts - Newser
Is Y mAbs Therapeutics Inc. stock risky to hold now2025 Price Targets & Growth-Oriented Investment Plans - thegnnews.com
Signal strength of Y mAbs Therapeutics Inc. stock in tech scannersJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - Newser
Can Y mAbs Therapeutics Inc. scale operations efficientlyWeekly Trade Review & Expert Curated Trade Ideas - thegnnews.com
What institutional flow reveals about Y mAbs Therapeutics Inc.July 2025 PostEarnings & Community Consensus Trade Alerts - Newser
Intraday pattern recognizer results for Y mAbs Therapeutics Inc.Weekly Gains Report & AI Driven Price Forecasts - Newser
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock - MSN
Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease - insights.citeline.com
Y-mAbs Therapeutics’ SWOT analysis: acquisition shakes up oncology stock outlook - Investing.com Nigeria
Y-mAbs soars on take-private deal with SERB Pharmaceutical - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, YMAB, DNOW on Behalf of Shareholders - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WideOpenWest, Inc. (NYSEWOW), BankFinancial Corporation (NasdaqBFIN), STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nas - Morningstar
Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Brookline Capital Management - MarketBeat
How Efficient Is Y mAbs Therapeutics Inc. at Controlling Operating CostsShort Term Opportunity Finder with Tools - Newser
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Truist Financial - MarketBeat
Analyzing Y mAbs Therapeutics Inc. with risk reward ratio chartsOversold Reversal Picks with Buy Zone - Newser
DeFi Technologies Provides Monthly Corporate Update: Valour Reports US$947 Million (C$1.3 Billion) in AUM, and Monthly Net Inflows of US$14.4 Million (C$19.8 Million) in July 2025, Among Other Key Developments - The Globe and Mail
Y-mAbs Therapeutics (NASDAQ:YMAB) Given Hold Rating at Jones Trading - MarketBeat
11 Best Short-Term Stocks to Invest in - Insider Monkey
Chart based analysis of Y mAbs Therapeutics Inc. trendsYearly Trend Summary and Opportunity Breakdown - Newser
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Neutral" Rating from HC Wainwright - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) - Eastern Progress
SERB Pharmaceuticals Acquires Y-MAbs As Revenue Slides - Finimize
Y-mAbs Therapeutics 2025 Q2 Earnings Narrowed Losses and Pending Acquisition - AInvest
HC Wainwright Downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) to Hold - Defense World
Y-mAbs Therapeutics Reports Q2 Earnings and Acquisition - TipRanks
Y-mAbs (YMAB) Q2 Revenue Falls 14% - AOL.com
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Y Mabs Therapeutics Inc Stock (YMAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rossi Michael J | PRESIDENT & CEO |
Mar 07 '25 |
Sale |
5.20 |
3,917 |
20,368 |
137,083 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Mar 07 '25 |
Sale |
5.23 |
10,810 |
56,536 |
202,721 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):